Genocea Biosciences, Inc.

OTCPK:GNCA.Q Voorraadrapport

Marktkapitalisatie: US$5.9k

Genocea Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Genocea Biosciences has been growing earnings at an average annual rate of 13.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 40.6% per year.

Belangrijke informatie

13.2%

Groei van de winst

32.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei40.6%
Rendement op eigen vermogen-300.3%
Nettomarge-1,946.2%
Laatste winstupdate31 Mar 2022

Recente prestatie-updates uit het verleden

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet

What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 18
What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?

Jan 14
How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?

Opbrengsten en kosten

Hoe Genocea Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

OTCPK:GNCA.Q Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Mar 222-371544
31 Dec 212-331540
30 Sep 212-351537
30 Jun 210-361535
31 Mar 211-431533
31 Dec 201-441434
30 Sep 201-381433
30 Jun 201-411332
31 Mar 200-361230
31 Dec 190-391227
30 Sep 190-291226
30 Jun 190-301326
31 Mar 190-271424
31 Dec 180-281425
30 Sep 180-391458
30 Jun 180-481452
31 Mar 180-591346
31 Dec 170-571339
30 Sep 170-62150
30 Jun 170-58150
31 Mar 170-54150
31 Dec 160-50150
30 Sep 160-44150
30 Jun 161-41150
31 Mar 161-40150
31 Dec 151-42140
30 Sep 151-44130
30 Jun 151-43120
31 Mar 150-40110
31 Dec 140-35100
30 Sep 140-3190
30 Jun 140-2780
31 Mar 140-2560
31 Dec 131-2250
30 Sep 131-2140
30 Jun 131-2040
31 Mar 132-1740
31 Dec 122-1540

Kwaliteitswinsten: GNCA.Q is currently unprofitable.

Groeiende winstmarge: GNCA.Q is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: Insufficient data to determine if GNCA.Q's year-on-year earnings growth rate was positive over the past 5 years.

Versnelling van de groei: Unable to compare GNCA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: GNCA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Rendement op eigen vermogen

Hoge ROE: GNCA.Q has a negative Return on Equity (-300.29%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden